Vnitr Lek 2020, 66(4):e36-e41 | DOI: 10.36290/vnl.2020.078

Liver fibrosis

Václav ©míd
IV. interní klinika - klinika gastroenterologie a hepatologie 1. LF UK a VFN Praha

Liver fibrosis is the excessive deposition of extracellular matrix in liver tissue resulting in structural and functional liver changes. The basis for these changes is the imbalance between fibrogenesis and fibrolysis, which arises in response to chronic liver damage, regardless of its aetiology. Advanced liver fibrosis leads to cirrhosis with its possible complications - portal hypertension, hepatocellular carcinoma, and liver failure. For patients with chronic liver disease, the development of liver fibrosis as well as its severity is the most important prognostic factor. Early diagnosis is a key to avoid above mentioned complications. Understanding the molecular mechanisms underlying liver fibrogenesis is fundamentally relevant to developing new antifibrotic treatments that are independent of the underlying aetiology.

Keywords: diagnosis of liver fibrosis, extracellular matrix, hepatic stellate cells, liver fibrosis, therapy of liver fibrosis.

Published: June 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©míd V. Liver fibrosis. Vnitr Lek. 2020;66(4):e36-41. doi: 10.36290/vnl.2020.078.
Download citation

References

  1. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210. Go to original source... Go to PubMed...
  2. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218. Go to original source... Go to PubMed...
  3. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003; 38: (Suppl. 1): S38-S53. Go to original source... Go to PubMed...
  4. van der Meer AJ, et al. Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. Gut 2015; 64: 322-331. Go to original source... Go to PubMed...
  5. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014; 383: 1749-1761. Go to original source... Go to PubMed...
  6. De Leeuw AM, Brouwer A, Knook DL. Sinusoidal endothelial cells of the liver: fine structure and function in relation to age. J Electron Microsc Tech 1990; 14: 218-236. Go to original source... Go to PubMed...
  7. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 2001; 21: 311-335. Go to original source... Go to PubMed...
  8. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011; 25: 195-206. Go to original source... Go to PubMed...
  9. Canbay A, et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003; 83: 655-663. Go to original source... Go to PubMed...
  10. Kocabayoglu P, Friedman SL. Cellular basis of hepatic fibrosis and its role in inflammation and cancer. Front Biosci (Schol Ed) 2013; 5: 217-230. Go to original source... Go to PubMed...
  11. Schuppan D, et al. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001; 21: 351-372. Go to original source... Go to PubMed...
  12. Trautwein C, et al. Hepatic fibrosis: Concept to treatment. J Hepatol 2015; 62: (1 Suppl.): S15-S24. Go to original source... Go to PubMed...
  13. Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non‑invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20: 475-485. Go to original source... Go to PubMed...
  14. Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321. Go to original source... Go to PubMed...
  15. Stasi C, Milani S. Non‑invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost‑effectiveness. World J Gastroenterol 2016; 22: 1711-1720. Go to original source... Go to PubMed...
  16. Angulo P, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362. Go to original source... Go to PubMed...
  17. Wai CT, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526. Go to original source... Go to PubMed...
  18. Vallet‑Pichard A, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-36. Go to original source... Go to PubMed...
  19. Angulo P, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854. Go to original source... Go to PubMed...
  20. Guechot J, et al. Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. Clin Chim Acta 2010; 411: 86-91. Go to original source... Go to PubMed...
  21. Guha IN, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 455-460. Go to original source... Go to PubMed...
  22. Bansal MB, Chamroonkul N. Antifibrotics in liver disease: are we getting closer to clinical use? Hepatol Int 2018; in press; online https://doi.org/10.1007/s12072-018-9897-3. Go to original source... Go to PubMed...
  23. Cohen‑Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol 2011; 4: 391-417. Go to original source... Go to PubMed...
  24. Marcellin P, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open‑label follow‑up study. Lancet 2013; 381: 468-475. Go to original source... Go to PubMed...
  25. Romero‑Gomez M, Zelber‑Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 2017; 67: 829-846. Go to original source... Go to PubMed...
  26. Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest 2013; 123: 1887-1901. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.